Cardiac arrest & resuscitation
The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest
Authors' conclusion
Levosimendan use in ECPR did not improve survival.
Study context
- Population
- Patients with refractory cardiac arrest supported by extracorporeal cardiopulmonary resuscitation (ECPR)
- Participants
- 87 patients
- Exposure
- Levosimendan vs no levosimendan in ECPR
- Levosimendann = 18
Methodological detailssingle tertiary academic center
- Single tertiary academic center
Main finding
As reported in the abstract
- Survival to decannulation: no difference (27.8% vs 26.1%)
- Survival to hospital discharge: no difference (27.8% vs 24.6%)
Observational data: associations, not effects.
Further findings
Highest lactate between the second and the fourth days after ECPR · significantly higher with levosimendan
P = 0.046
Duration of ECMO support · significantly longer with levosimendan
P = 0.0019
Survival to decannulation
- No difference between the groups
Survival to hospital discharge
- No difference between the groups
ICU LOS
- No difference between the groups
Hospital LOS
- No difference between the groups
Safety
Complications (eg, infection, bleeding, arrhythmias)
- No difference between the groups in complication rates
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest. J Cardiothorac Vasc Anesth. Published 11 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →